



STOP AT NOTHING



*Actor portrayal

PATIENT GUIDE

Upravi 
selexipag
tablets | 200/600 mcg

DELAY PAH
PROGRESSION,

NOT
FAMILY PLANS



*Actor portrayal

**UPTRAVI® (SELEXIPAG) IS THE ONLY ORAL
PROSTACYCLIN PATHWAY THERAPY APPROVED TO:**

➤ Delay disease progression*

➤ Reduce the risk of
PAH-related hospitalization

UPTRAVI® can also improve the ability to exercise
(as measured by the 6-minute walk test)

SIDE EFFECTS

Side effects occurring more frequently (by $\geq 3\%$) for patients on UPTRAVI® compared to patients on placebo (sugar pill) are headache, diarrhea, jaw pain, nausea, muscle pain, vomiting, pain in arms or legs, temporary reddening of the skin (flushing), joint pain, low red blood cell count, less appetite than usual, and rash.

The clinical trial for UPTRAVI® included 1156 PAH patients — comparing 574 patients taking UPTRAVI® to 582 patients taking a placebo (sugar pill). Nearly all patients fell within Functional Class II or III (PAH patients range from Functional Class I to IV). Patients on UPTRAVI® were treated for up to 4.2 years during this study. The median amount of time treated was 1.4 years. The mean age was 48 years; the majority of patients were white (65%) and female (80%).

*In a clinical trial of UPTRAVI®, PAH disease progression was defined as a serious event, such as hospitalization for PAH; the need to start injectable PAH medications or chronic oxygen therapy; atrial septostomy (a procedure where a hole is placed between two small chambers of the heart) or lung transplantation; a decline in 6-minute walk distance (6MWD) combined with worsening of functional class (FC) or need for additional PAH therapy; or death.

What is UPTRAVI® (selexipag)?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

What is UPTRAVI® (selexipag)? (continued)

UPTRAVI® can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH. It is not known if UPTRAVI® is safe and effective in children.

SUPPORTING PEOPLE JUST LIKE YOU

“ When I hear a medicine can delay my disease progression, it gives me confidence. ”

— Emily (Person Living With PAH on UPTRAVI®)

Hear more about Emily's PAH journey with UPTRAVI® here.

Individual results may vary.

Emily is a patient advocate part of the SHARE Network, a program made up of people who are dedicated to inspiring others through their personal health journeys and stories of caring. She is a real patient with PAH and was compensated by Actelion Pharmaceuticals US, Inc., for her time to develop this content.

We're proud to say that UPTRAVI® (selexipag) was proven safe in the largest trial of any FDA-approved PAH treatment.

10
YEARS

of safety data,
the longest follow-up period of
any PAH therapy



Actor portrayal

SELECT IMPORTANT SAFETY INFORMATION

- Do not take UPTRAVI® (selexipag) if you take gemfibrozil because this medicine may affect how UPTRAVI® works and cause side effects
- Do not take UPTRAVI® if you are allergic to selexipag or any of the ingredients in UPTRAVI®

SELECT IMPORTANT SAFETY INFORMATION (continued)

- Before you take UPTRAVI® (selexipag), tell your healthcare provider about all your medical conditions, including if you:
 - Have liver problems
 - Have narrowing of the pulmonary veins (veins in your lungs). This is called pulmonary veno-occlusive disease (PVOD)

**TREATMENT WITH
UPTRAVI® (SELEXIPAG)
ALLOWS FOR DOSING FOR
WHEREVER LIFE TAKES YOU.**

Like some other PAH medications, UPTRAVI® has a Dose Adjustment (Titration) Phase, which is an initial part of treatment until you reach the dose that's right for you.


UPTRAVI® Tablet dose strengths range from 200 mcg to 1600 mcg, but that doesn't mean you have to reach the highest dose of UPTRAVI® to find your personal dose.



**THE ORAL DOSING OF UPTRAVI®
AVOIDS INJECTIONS, INHALERS, AND
THE NEED FOR SPECIAL EQUIPMENT.**



**UPTRAVI® AVOIDS
THE NEED FOR ROUTINE
BLOOD MONITORING.**



**WITH UPTRAVI® TWICE-DAILY
ORAL PILLS, YOU CAN TAKE YOUR
MEDICATION WHEREVER YOU GO.**

*Actor portrayal

SELECT IMPORTANT SAFETY INFORMATION (continued)

• **Before you take UPTRAVI® (selexipag), tell your healthcare provider about all your medical conditions, including if you: (continued)**

- Are pregnant or plan to become pregnant. It is not known if UPTRAVI® will harm your unborn baby

SELECT IMPORTANT SAFETY INFORMATION (continued)

• **Before you take UPTRAVI® (selexipag), tell your healthcare provider about all your medical conditions, including if you: (continued)**

- Are breastfeeding or plan to breastfeed. It is not known if UPTRAVI® passes into your breast milk. You and your doctor should decide if you will take UPTRAVI® or breastfeed. You should not do both
- Are taking any other prescription or over-the-counter medicines, vitamins, or herbal supplements

Get started on a treatment plan that's right for you.
Learn more about UPTRAVI® (selexipag).

#1 MOST- PRESCRIBED ORAL PROSTACYCLIN PATHWAY THERAPY NATIONWIDE.*

*Based on yearly prescription and refill data
from US claims (1/24-10/24).



*Actor portrayal

THERE ARE 3 FOUNDATIONAL PATHWAYS YOU CAN TARGET TO TREAT YOUR PAH:

Nitric Oxide

Endothelin

Prostacyclin

UPTRAVI® (selexipag)
works here.

Arteries in your lungs may be affected when there is either too much or too little of these naturally occurring substances in your body.

Ask your doctor if early treatment with UPTRAVI® may be right for you.

SELECT IMPORTANT SAFETY INFORMATION (continued)

What are the possible side effects of UPTRAVI®?

The most common side effects are:

- Headache
- Diarrhea
- Jaw pain
- Nausea
- Muscle pain
- Vomiting
- Pain, redness or swelling at the injection site with UPTRAVI® for injection
- Pain in arms or legs

SELECT IMPORTANT SAFETY INFORMATION (continued)

What are the possible side effects of UPTRAVI®? (continued)

The most common side effects are:

- Temporary reddening of the skin (flushing)
- Joint pain
- Low red blood cell count
- Less appetite than usual
- Rash

Once you and your healthcare provider have decided that UPTRAVI® (selexipag) is right for you, gain access to patient support programs.

TAKE ON PAH WITH PATIENT SUPPORT

UPTRAVI® Titration Education Program

During these visits, the nurse can:

- Educate you on what to expect as you start therapy with UPTRAVI®
- Educate you on any potential misconceptions about UPTRAVI® dosing
- Ensure you have understanding of reaching your personal dose
- Provide you and/or your caregiver with recommendations on when to call your treating healthcare professional (HCP)

You may choose to receive titration education as you start therapy. The program is delivered to you virtually (by video or phone) or in-home, depending on you and your provider's preference.

UPTRAVI® Titration Education Program is not intended to provide medical advice, replace a treatment plan you receive from your healthcare team, or serve as a reason for you to start or stay on treatment.

With a PAH portfolio spanning decades of experience, Johnson & Johnson remains committed to serving people living with PAH. We offer a variety of educational resources and support programs to assist you along the way.

J&J withMe

J&J withMe will help you find the resources you may need to get started and stay on track. We will give you information on your insurance coverage, potential out-of-pocket costs, and treatment support, and identify options that may help make your treatment more affordable.

Visit [JNJwithMe.com/UPTRAVI](https://www.jnjwithme.com/UPTRAVI)

If you have questions, call a J&J withMe Care Coordinator at 866-228-3546, Monday-Friday, 8:00 AM–8:00 PM ET. Multilingual phone support is available.

PAH Companion withMe*

PAH Companion withMe is part of the J&J withMe suite of patient support resources customized for your specific needs, questions, and interests. One-on-one educational conversations with a dedicated PAH Companion — coupled with access to current PAH tools and resources — helps you take a more active role in your care.

Your dedicated PAH Companion is ready to listen, understand and support you throughout your treatment experience. You can connect with your PAH Companion by calling 866-300-1818, Monday–Friday, 8 AM–9 PM ET.

Learn more at [pahcompanion.com](https://www.pahcompanion.com).

The support and resources provided by J&J withMe and PAH Companion withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.

*PAH Companion withMe requires a completed patient authorization form to enroll.



*Actor portrayal.

Learn more about available support resources [here](#).

SELECT IMPORTANT SAFETY INFORMATION (continued)

What are the possible side effects of UPTRAVI® (selexipag)? (continued)

Talk to your doctor if you have a side effect that bothers you or does not go away. These are not all the possible side effects of UPTRAVI®. For more information, ask your doctor or pharmacist.

SELECT IMPORTANT SAFETY INFORMATION (continued)

What are the possible side effects of UPTRAVI® (selexipag)? (continued)

You may report side effects to **FDA at 1-800-FDA-1088 or www.fda.gov/medwatch**. Keep UPTRAVI® and all other medicines away from children.

IMPORTANT SAFETY INFORMATION

What is UPTRAVI® (selexipag)?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

UPTRAVI® can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.

It is not known if UPTRAVI® is safe and effective in children.

Important Safety Information

- **Do not take UPTRAVI® if you** take gemfibrozil because this medicine may affect how UPTRAVI® works and cause side effects
- **Do not take UPTRAVI® if you** are allergic to selexipag or any of the ingredients in UPTRAVI®
- **Before you take UPTRAVI®, tell your healthcare provider about all your medical conditions, including if you:**
 - Have liver problems
 - Have narrowing of the pulmonary veins (veins in your lungs). This is called pulmonary veno-occlusive disease (PVOD)
 - Are pregnant or plan to become pregnant. It is not known if UPTRAVI® will harm your unborn baby
 - Are breastfeeding or plan to breastfeed. It is not known if UPTRAVI® passes into your breast milk. You and your doctor should decide if you will take UPTRAVI® or breastfeed. You should not do both
 - Are taking any other prescription or over-the-counter medicines, vitamins, or herbal supplements

What are the possible side effects of UPTRAVI®?

The most common side effects are:

- Headache
- Vomiting
- Diarrhea
- Pain, redness or swelling at the injection site with UPTRAVI® for injection
- Jaw pain
- Pain in arms or legs
- Nausea
- Muscle pain
- Temporary reddening of the skin (flushing)
- Joint pain
- Low red blood cell count
- Less appetite than usual
- Rash

IMPORTANT SAFETY INFORMATION (continued)

What are the possible side effects of UPTRAVI® (selexipag)? (continued)

Talk to your doctor if you have a side effect that bothers you or does not go away. These are not all the possible side effects of UPTRAVI®. For more information, ask your doctor or pharmacist.

You may report side effects to **FDA at 1-800-FDA-1088 or www.fda.gov/medwatch**.

Keep UPTRAVI® and all other medicines away from children.

What other medicines might interact with UPTRAVI®?

UPTRAVI® and other medicines may affect each other, causing side effects. Tell your doctor about all the medicines you are taking. Do not start any new medicine until you check with your doctor.

How should I take UPTRAVI®?

UPTRAVI® Tablets

- Take UPTRAVI® exactly as your doctor tells you to take it. Usually, your doctor will have you take UPTRAVI® twice a day. Taking UPTRAVI® with food may help you tolerate UPTRAVI® better
- Swallow UPTRAVI® tablets whole. Do not split, crush, or chew tablets
- Tell your doctor if you have any form of liver disease. Your doctor may need to change your dose of UPTRAVI®
- UPTRAVI® is measured in micrograms (mcg). Tablets come in the following strengths: 200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg

UPTRAVI® given by intravenous (IV) injection

- Your healthcare provider will give you UPTRAVI® into your vein through an intravenous (IV) line
- Your healthcare provider will decide how much UPTRAVI® for injection you will receive each day based on your current dose of UPTRAVI® tablets

Please [click here](#) to read full Prescribing Information and Patient Product Information for UPTRAVI® and discuss any questions you have with your doctor.

cp-113991v5

PROCEED WITH CONFIDENCE

Talk to your doctor to learn even more about how UPTRAVI® (selexipag) may delay your PAH disease progression.

Sign up to receive information about PAH, how UPTRAVI® (selexipag) works, and how you can talk to your doctor about treatment [here](#).

*Actor portrayal

Johnson & Johnson

© Johnson & Johnson and its affiliates 2025 02/25 cp-470062v2